<![CDATA[Genmab - Phase 3 MAIA Study - Significant overall Survival]]>Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress.

https://www.businesswire.com/news/home/20210612005027/en/ Janssen-Announces-Results-from-Phase-3-MAIA-Study-Showing-Significant-Ov

]]>https://dev.proinvestor.com/forum/topic/442758/genmab-phase-3-maia-study-significant-overall-survivalRSS for NodeMon, 06 Jul 2026 19:19:52 GMTSat, 12 Jun 2021 05:44:02 GMT60<![CDATA[Reply to Genmab - Phase 3 MAIA Study - Significant overall Survival on Sat, 12 Jun 2021 06:06:01 GMT]]>Det er outstanding resultater. En vidunderlig udvikling for patienterne som Genmab og Janssen har lykkedes med indtil videre indenfor knoglemarvskæft.

]]>https://dev.proinvestor.com/forum/post/9467926https://dev.proinvestor.com/forum/post/9467926Sat, 12 Jun 2021 06:06:01 GMT